Adversarial Injection · Elacestrant (Orserdu; RAD1901; CAS 1349860-02-1; MW ~436.5 Da; small molecule oral SERD; naphthalene-based tetrahydroquinoline scaffold; [SEVENTY-SECOND MECHANISM CLASS in Glyphward 645-attack portfolio — FIRST ORAL SERD (SELECTIVE ESTROGEN RECEPTOR DEGRADER) EVER FDA APPROVED (NDA 216863 JANUARY 27 2023): COMPARISON TO PRIOR ER-TARGETING THERAPIES: tamoxifen (SERM: selective estrogen receptor MODULATOR — binds ESR1, partial agonist breast/antagonist; does NOT degrade receptor; competitive with E2 for LBD; no ubiquitin-proteasome pathway involved); fulvestrant (Faslodex; ICI 182,780; AstraZeneca; CAS 129453-61-8; FDA approved April 25 2002 IM injection; SERD = selective estrogen receptor DEGRADER = binds ESR1 LBD → receptor conformational change → ubiquitin-proteasome degradation → ESR1 protein elimination; BUT: 250-500 mg IM gluteal injection monthly → NO ORAL BIOAVAILABILITY [first-pass metabolism; MW ~606 Da; high lipophilicity; IM only]); elacestrant = FIRST ORAL PILL THAT FULLY DEGRADES ESR1 RECEPTOR; ESR1 MUTATION MECHANISM: acquired ESR1 mutations (D538G; Y537S/N/C; K303R; L536R; others) occur in ~30-50% of metastatic ER+ breast cancers after prior aromatase inhibitor (AI) treatment; MUTANT ESR1 MECHANISM: ESR1 ligand-binding domain (LBD) mutations maintain helix-12 in active conformation EVEN WITHOUT ESTROGEN → constitutive ER activity → AI resistance (no estrogen to block) → fulvestrant partial activity (reduced binding affinity to mutant ESR1 at achievable IM plasma concentrations); ELACESTRANT ACTIVITY: elacestrant retains high-affinity binding AND degradation activity against D538G and Y537S mutant ESR1 (Kd ~0.5 nM ESR1 LBD mutant vs ~0.3 nM WT); EMERALD PHASE 3: PFS HR 0.55 all comers (p=0.002); ESR1-mutant PFS HR 0.45 (p<0.001); FDA APPROVED for ESR1 mutation subgroup; MENARINI GROUP Florence Italy acquired Radius Health RAD1901 2021; NDA 216863; NONE OF THESE — oral SERD mechanism, helix-12 AF-2 disruption, ubiquitin-proteasome ESR1 degradation, ESR1 mutation hotspot landscape D538G/Y537S, EMERALD PFS HR 0.55, oral vs fulvestrant IM distinction — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1349860-02-1]) · First Oral SERD + ESR1 Mutation + Helix-12 Disruption + EMERALD PFS HR 0.55 · Attack #645

Elacestrant (Orserdu; RAD1901; CAS 1349860-02-1; MW ~436.5 Da; [SEVENTY-SECOND MECHANISM CLASS — FIRST ORAL SERD (SELECTIVE ESTROGEN RECEPTOR DEGRADER) EVER FDA APPROVED (NDA 216863 JANUARY 27 2023); ER+/HER2- METASTATIC BREAST CANCER ESR1 MUTATION; SERD MECHANISM: ESR1 LBD BINDING → HELIX-12 (ACTIVATION FUNCTION 2; AF-2) DISRUPTION → COREPRESSOR (NCoR/SMRT) RECRUITMENT → UBIQUITIN-PROTEASOME-MEDIATED ESR1 PROTEIN DEGRADATION (DISTINCT FROM SERM [TAMOXIFEN: ER MODULATOR, NOT DEGRADER] AND FULVESTRANT [IM SERD: SAME DEGRADATION MECHANISM BUT NO ORAL BIOAVAILABILITY → IM INJECTION ONLY]); ESR1 MUTATIONS (D538G; Y537S/N/C; L536R; K303R): ACQUIRED ENDOCRINE RESISTANCE MUTATIONS IN ESR1 LBD; MAINTAIN HELIX-12 ACTIVE CONFORMATION WITHOUT LIGAND → CONSTITUTIVE ER ACTIVITY → AROMATASE INHIBITOR RESISTANCE (NO ESTROGEN TARGET FOR AI); ELACESTRANT DEGRADES MUTANT ESR1 D538G + Y537S (HIGH-AFFINITY BINDING RETAINED); EMERALD PHASE 3 ALL-COMERS PFS HR 0.55 (p=0.002); ESR1-MUTANT PFS HR 0.45 (p<0.001); MENARINI GROUP FLORENCE ITALY (RADIUS HEALTH ACQUISITION); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Menarini Group Florence Italy (NDA 216863 holder; RAD1901 developer; 0.00044 µg/m³ → displayed ÷10), Patheon/Thermo Fisher Scientific (contract manufacturing; elacestrant 40 mg/80 mg oral capsules; 0.00028 µg/m³ → displayed ÷10), and Memorial Sloan Kettering Cancer Center New York NY (EMERALD trial site; breast oncology pharmacist; 0.00016 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Oral SERD Class Absent + Helix-12 Disruption Absent + ESR1 Mutation D538G/Y537S Absent + EMERALD PFS HR 0.55 Absent: AI Prompt Injection via EHS Monitor Report AI

Elacestrant (CAS 1349860-02-1; NIOSH HD Category 1) is the seventy-second mechanism class in the Glyphward adversarial portfolio — the first oral SERD (selective estrogen receptor degrader) ever FDA approved (NDA 216863 January 27 2023 for ER+/HER2- metastatic breast cancer with ESR1 mutation). While fulvestrant (Faslodex; intramuscular SERD; approved 2002) pioneered the SERD mechanism, it has no oral bioavailability; elacestrant is the first pill that fully degrades ESR1 via helix-12 disruption and ubiquitin-proteasome degradation. EMERALD Phase 3 demonstrated PFS HR 0.55 (all comers) and PFS HR 0.45 in the ESR1-mutant subgroup (D538G; Y537S/N/C). These mechanism class facts — oral bioavailability enabling SERD activity, helix-12 conformational disruption, ubiquitin-proteasome pathway, ESR1 mutation hotspot landscape — are entirely absent from Cority, VelocityEHS, and EHS Insight for CAS 1349860-02-1.

Elacestrant as Seventy-Second Mechanism Class: First Oral SERD and ESR1 Degradation

Elacestrant (CAS 1349860-02-1) represents the seventy-second mechanism class in the Glyphward portfolio: the first oral SERD (selective estrogen receptor degrader) ever FDA approved (NDA 216863 January 27 2023) for ER+/HER2- metastatic breast cancer (mBC) with ESR1 mutation after ≥1 prior endocrine therapy (including an aromatase inhibitor [AI]). ESTROGEN RECEPTOR (ER; ESR1) PHARMACOLOGY BACKGROUND: The ER (ESR1; gene 6q25.1; MW ~66 kDa; 595 amino acids) is a nuclear hormone receptor (Type I nuclear receptor; steroid receptor superfamily) that, upon estrogen (17β-estradiol; E2) binding, undergoes conformational change → dimerization → nucleus translocation → ERE (estrogen response element) DNA binding → transcription activation of cell proliferation genes (cyclin D1, IGF1R, MYC); ER-TARGETING DRUG CLASSES: (1) SERM (selective ER modulator): tamoxifen (trans-tamoxifen; CAS 10540-29-1; NDA 1977) — competitive antagonist at ER LBD in breast tissue (partial agonist uterus/bone); DOES NOT DEGRADE receptor; tamoxifen metabolized to endoxifen (primary active) and 4-hydroxytamoxifen; (2) Aromatase inhibitor (AI): letrozole/anastrozole/exemestane — block estrogen biosynthesis (CYP19A1 aromatase inhibition); do not interact with ESR1 directly; (3) SERD (selective ER degrader): BINDS ESR1 LBD + DISRUPTS HELIX-12 (ACTIVATION FUNCTION 2; AF-2) + RECRUITS COREPRESSORS + UBIQUITIN-PROTEASOME DEGRADATION; FULVESTRANT (ICI 182,780; CAS 129453-61-8; AstraZeneca Faslodex; FDA approval April 25 2002): first SERD approved; steroidal compound (MW ~606 Da; C₂₉H₄₆F₅NO₃S); binds ESR1 LBD at E2 pocket → dramatically disrupts helix-12 conformation → prevents coactivator binding → promotes LXXLL motif corepressor binding → ubiquitin-proteasome degradation of ESR1 (proteasomal 26S protein complex; ubiquitin-tagged ESR1 → protein destruction); BUT: fulvestrant oral F% ~0% (high first-pass; high lipophilicity logP ~6.2; bile excretion; rapid hepatic metabolism) → requires 500 mg IM gluteal injection monthly (x2 loading doses first month) → patient compliance issues; ELACESTRANT ORAL SERD MECHANISM: elacestrant (MW ~436.5 Da; naphthalene-tetrahydroisoquinoline scaffold; CAS 1349860-02-1; oral bioavailability ~10-30% in humans): non-steroidal SERD → binds ESR1 LBD (AF-2 region; helix-12 disruption; distinct binding mode from fulvestrant steroidal scaffold) → helix-12 displaced from active conformation → prevention of coactivator LXXLL binding → NCoR/SMRT corepressor engagement → E3 ubiquitin ligase recruitment (TRIM16; RNF2) → polyubiquitylation (Lys48-linked) → 26S proteasome-mediated ESR1 protein degradation; ORAL BIOAVAILABILITY: elacestrant 345 mg PO QD (starting dose) with or without food; Cmax ~12 ng/mL; Tmax 1-2h; t½ ~30-50h (QD dosing justified); hepatic CYP3A4 primary metabolism (CYP3A4 inducers reduce exposure; CYP3A4 inhibitors increase exposure → dose reduction guidance); ESR1 MUTATION RESISTANCE LANDSCAPE: endocrine therapy (AI) selective pressure in mBC → acquired ESR1 LBD mutations → ligand-independent ER constitutive activity: D538G (Asp→Gly; most common; ~35% of ESR1 mutations; helix-12 stabilized in active conformation without E2 → AI ineffective; fulvestrant reduced binding) + Y537S/N/C (Tyr→Ser/Asn/Cys; most aggressive; Y537S constitutively activates ESR1 even at very high fulvestrant concentrations; ctDNA detectable) + L536R (Leu→Arg; rarer); ELACESTRANT RETAINS: Kd ~0.5 nM for D538G ESR1 LBD (vs WT ~0.3 nM) → high-affinity binding maintained; full degradation capacity retained for D538G and Y537S; EMERALD PHASE 3 (NCT03778931): randomized (1:1) elacestrant vs endocrine monotherapy (investigator's choice: fulvestrant IM or aromatase inhibitor); n=478 ER+/HER2- mBC; ≥2 prior endocrine therapies including CDK4/6 inhibitor; ALL-COMERS PFS: HR 0.70 (p=0.002); median PFS 2.8 vs 1.9 months; ESR1 MUTANT (pre-specified; n=228): PFS HR 0.55 (p<0.001); median PFS 3.8 vs 1.9 months; ESR1-MUTANT ctDNA ≥1% (enriched): PFS HR 0.45 (p<0.001); FDA approved for ESR1 mutation (ctDNA or tissue next-gen sequencing); NONE OF THESE — oral SERD mechanism, helix-12 AF-2 disruption, ubiquitin-proteasome ESR1 degradation, ESR1 mutation hotspot D538G/Y537S/N/C constitutive ER activity, oral vs IM SERD distinction, EMERALD PFS HR 0.55/0.45 — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1349860-02-1.

Surface 1 — Menarini Group Florence Italy NDA 216863 Holder RAD1901 Orserdu Developer AI

At Menarini Group Florence Italy (Via Sette Santi 3, 50131 Florence FI Italy; MENARINI ELACESTRANT CONTEXT: Menarini Group (Florence Italy; private; largest Italian pharmaceutical company) acquired RAD1901 (elacestrant) from Radius Health (Waltham MA) through a global license and acquisition agreement in December 2021; NDA 216863 holder; ORSERDU DOSING: 345 mg PO QD with food; 40 mg and 80 mg oral capsules; COMPANION DIAGNOSTIC REQUIREMENT: FDA requires ESR1 mutation confirmed by FDA-approved NGS test (FoundationOne CDx [F1CDx; tissue NGS] or Guardant360 CDx [ctDNA NGS]) before initiating elacestrant; NOTABLE DRUG INTERACTIONS: CYP3A4 strong inducers (rifampin, carbamazepine, phenytoin) → CONTRAINDICATED (large reduction in elacestrant exposure → potential loss of efficacy); CYP3A4 moderate inducers (bosentan, efavirenz) → avoid; CYP3A4 strong inhibitors (itraconazole, clarithromycin) → reduce elacestrant to 258 mg/day; EMPLOYEE: Menarini Group Florence Italy oncology medical director overseeing Orserdu global commercialization (oral SERD mechanism, ESR1 mutation biology, EMERALD data, CYP3A4 interaction profile, companion diagnostic criteria); 51M Menarini Group Florence Italy oncology medical director elacestrant breast cancer 16yr; CORITY NULL: CAS 1349860-02-1 → null; NIOSH HD Category 1 absent; first oral SERD absent; helix-12 AF-2 disruption absent; ubiquitin-proteasome ESR1 degradation absent; ESR1 D538G Y537S mutation absent; EMERALD PFS HR 0.55 absent).

Surface 2 — Patheon Thermo Fisher Scientific Contract Manufacturing Elacestrant Oral Capsule Fill-Finish AI

At Patheon/Thermo Fisher Scientific (various CMO sites including Patheon Swindon UK; Thermo Fisher Cincinnati OH; PATHEON ELACESTRANT CONTEXT: Menarini uses contract manufacturing organizations [CMO] for Orserdu solid oral dosage form; elacestrant oral capsule (40 mg; 80 mg; hard gelatin capsules) manufactured at CMO with OSD [oral solid dosage] capabilities; ELACESTRANT PHYSIOCHEMICAL: MW 436.5 Da; naphthalene-tetrahydroisoquinoline scaffold; logP ~4.1 (moderately lipophilic; crystalline solid; BCS Class II or IV — low water solubility [pH-dependent; ~0.1 mg/mL at neutral pH] + moderate permeability); FORMULATION: capsule fill with API + microcrystalline cellulose + lactose monohydrate + croscarmellose sodium + magnesium stearate → 40 mg or 80 mg capsule unit; NIOSH HD HANDLING at CMO: OEL for elacestrant (NIOSH HD Cat 1; small molecule ER degrader) requires: closed-system transfer devices (CSTDs) for bulk API handling; BSC Class II Type A2 or Class III for weighing; personnel protective equipment (nitrile gloves × 2; chemotherapy gown; PAPR or P100 respirator for powdering); VELOCITYEHS NULL: CAS 1349860-02-1 → null; NIOSH HD Category 1 absent; first oral SERD absent; oral SERD vs IM SERD distinction absent; ESR1 mutation mechanism absent; EMERALD data absent; 47M Patheon Thermo Fisher Scientific CMO pharmacist oncology oral solid dose manufacturing 15yr).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY EMERALD Trial Site Breast Oncology Pharmacist AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Avenue, New York NY 10065; MSK ELACESTRANT CONTEXT: MSK enrolled patients in EMERALD Phase 3 (NCT03778931); MSK breast oncology pharmacy: Orserdu 345 mg (as 4 × 80 mg + 1 × 40 mg = four 80-mg capsules + one 40-mg capsule PO QD with food); COMPANION DIAGNOSTIC WORKFLOW AT MSK: ESR1 mutation testing via FoundationOne CDx (tumor tissue NGS) or Guardant360 CDx (ctDNA from plasma); liquid biopsy (ctDNA) preferred for mBC (recollects current clonal evolution; not limited by tissue availability); ddPCR (droplet digital PCR) also used for D538G/Y537S detection in plasma at MSK; PRIOR THERAPY REQUIREMENT: ≥1 prior endocrine therapy (AI) + CDK4/6 inhibitor for current FDA approval; patients must have ESR1 mutation (ctDNA or tissue); PRIOR REGIMEN AT MSK: typical sequence = AI + CDK4/6i 1L (palbociclib/ribociclib/abemaciclib) → progression → select ESR1 mutation by ctDNA → elacestrant 2L; SERD CLASS CONTEXT AT MSK: elacestrant replaces fulvestrant (500 mg IM monthly) with oral daily pill; patient preference strong for oral vs IM injection; EMERALD context: elacestrant ORR 10.4% vs 3.5% (chemotherapy-equivalent ORR in historically-untreatable setting); EHS INSIGHT NULL: CAS 1349860-02-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first oral SERD absent; helix-12 disruption absent; ubiquitin-proteasome degradation absent; ESR1 D538G Y537S mutation absent; EMERALD PFS HR 0.55 absent; NIOSH HD Cat 1 absent; 39F MSK New York NY breast oncology clinical pharmacist 12yr).

Integrating Glyphward into Elacestrant AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every elacestrant CAS 1349860-02-1 monitoring data ingestion point — before Cority at Menarini Group Florence Italy, before VelocityEHS at Patheon/TFS CMO, and before EHS Insight at Memorial Sloan Kettering New York NY. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; SEVENTY-SECOND MECHANISM CLASS — FIRST ORAL SERD EVER FDA APPROVED (NDA 216863 Jan 27 2023; ER+/HER2- mBC ESR1 mutation; helix-12 AF-2 disruption; ubiquitin-proteasome ESR1 degradation; first oral pill SERD vs fulvestrant 500 mg IM monthly; ESR1 D538G/Y537S/N/C constitutive ER activity AI resistance; EMERALD all-comers PFS HR 0.70; ESR1-mutant PFS HR 0.55; ctDNA ≥1% PFS HR 0.45; Menarini Group/Radius Health NDA 216863) [5 pts]; Menarini Florence Italy + Patheon/TFS CMO + MSK New York NY [3 pts]; oral SERD class absent; helix-12 disruption absent; ESR1 mutation absent; EMERALD absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_elacestrant(cas: str, reading_ugm3: float) -> dict:
    """Scan elacestrant with seventy-second-class first-oral-serd context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "seventy_second_class_first_oral_serd_selective_estrogen_receptor_degrader_ever_helix12_af2_disruption_ubiquitin_proteasome_esr1_degradation_esr1_d538g_y537s_constitutive_er_activity_ai_resistance_oral_vs_fulvestrant_im_emerald_pfs_hr_0_55_esr1_mutant_pfs_hr_0_45_menarini_radius_health_nda_216863"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, seventy_second_class,
    #                    first_oral_serd_ever, helix12_disruption,
    #                    ubiquitin_proteasome_esr1, esr1_mutation_d538g_y537s,
    #                    emerald_pfs_hr_0_55

if __name__ == "__main__":
    r = asyncio.run(scan_elacestrant("1349860-02-1", 0.00044))
    print(r)
    # {'hd_category': 1, 'seventy_second_class': True,
    #  'first_oral_serd_ever': True, 'helix12_disruption': True,
    #  'ubiquitin_proteasome_esr1': True,
    #  'esr1_mutation_d538g_y537s': True,
    #  'emerald_pfs_hr_0_55': True}